Compare
Vor Biopharma Inc. vs Monte Rosa Therapeutics, Inc. vs Scilex Holding Co vs Bio-Techne Corp
| Latest fiscal year | Vor Biopharma Inc. VOR | Monte Rosa Therapeutics, Inc. GLUE | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Bio-Techne Corp TECH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $123.67M | $30.25M | $1.22B |
| Revenue growth (YoY) | n/a | +63.5% | -46.5% | -0.4% |
| Gross margin | n/a | n/a | 65.0% (computed) | 65.8% |
| Operating margin | n/a | -43.8% | n/m | 20.7% |
| Net margin | n/a | -31.2% | n/m | 15.0% |
| Net income | -$695.98M | -$38.63M | -$374.05M | $181.86M |
| EPS (Diluted) | -$70.50 | n/a | -$36.48 | $1.16 |
| Operating cash flow | -$142.71M | -$22.80M | $3.82M | $292.07M |
| Free cash flow | -$143.65M | -$27.50M | $3.68M | $263.22M |
| Cash & equivalents | $396.49M | $129.88M | $4.96M | $264.71M |
| Total assets | $464.13M | $448.66M | $364.98M | $2.59B |
| Total liabilities | $628.44M | $215.60M | $576.73M | n/a |
| Shareholders' equity | -$164.31M | $233.06M | -$207.78M | $2.11B |
| Return on year-end equity | n/a | -16.6% | n/a | 8.6% |
| Shares outstanding | 38.72M | 65.54M | 7.03M | 156.10M |
Revenue, most recent five fiscal years
| Fiscal year | Vor Biopharma Inc. | Monte Rosa Therapeutics, Inc. | Scilex Holding Co | Bio-Techne Corp |
|---|---|---|---|---|
| Latest | n/a | $123.67M Ended 2025-12-31 | n/a | $1.22B Ended 2026-06-30 |
| 1 year earlier | n/a | $75.62M Ended 2024-12-31 | n/a | $1.22B Ended 2025-06-30 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | $1.16B Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | n/a | $1.14B Ended 2023-06-30 |
| 4 years earlier | n/a | n/a | n/a | $1.11B Ended 2022-06-30 |